Good morning, everyone. Another soggy day here on the Pharmalot corporate campus. Nonetheless, our spirits are sunny. As the Morning Mayor used to say: Every brand new day should be unwrapped like a precious gift. So while you tug on the ribbon, we will quaffe our mandatory cup of stimulation and continue scouring for interesting items. Hope your day goes well...
Par Pharma Used Medicaid To Overcharge (Bloomberg News)
J&J Vaginal Mesh Devices Faces FDA Panel & Lawsuits (Bloomberg News)
Teva Says ADHD Drug Met Study Goal (Associated Press)
Aurobindo Forms Joint Venture In Russia (Reuters)
AstraZeneca Pushes An R&D Makeover (The Boston Globe)
Novo Says WHO Should Buy Diabetes Drugs In Bulk (Bloomberg News)
J&J Zytiga Prostate Cancer Drug Approved In EU (Reuters)
Indian Judge Recuses Himself From Novartis Patent Hearing (Law Et Al News)
J&J Faces Third Trial Over Levaquin Tendon Injuries (Bloomberg News)
Teva Defense Of Copaxone Patent Begins (Pharma Times)
Glaxo Awarded BARDA Contract For Antibiotic Research (Dow Jones)
Former Merck Employees Sue Over Improper Wage Payments (The Record)
EDITOR'S NOTE: Please check this post for updates throughout the morning
rain pic thx to sterlic on flickr
1 Comment
Concerning 'Former Merck employees'
This sentence got my attention: "The defendant only paid the plaintiffs one time per month during the course of their employment instead of every two weeks [accordng to applicable state law], according to the suits."
And it took them how long to notice this? That would seem to be 'the crime."